The American Physiological Society Press Release

press release logo

APS Contact: APS Communications Office

Email: communications@the-aps.org

Phone: 301.634.7209

Twitter: @APSPhysiology


IV Administration of Endothelin B Receptor Drug Reduces Memory Loss, Oxidative Stress in Alzheimer’s Disease

Savannah, Ga. (September 4, 2015)An estimated 5.3 million people in the U.S. suffer from Alzheimer’s disease (AD)—the most common form of dementia—and roughly 473,000 people will develop the disease in 2015. There are currently five medications approved by the Food and Drug Administration (FDA) to treat AD. However, these drugs only help mask the symptoms and do not stop the disease from progressing or treat the underlying disease. In a new study presented at the 14th International Conference on Endothelin: Physiology, Pathophysiology and Therapeutics, researchers used IRL-1620, a chemical that binds to endothelin B receptors, to treat AD in rats.

Studies have shown that endothelin B receptors are important in brain development. “We used the novel approach of stimulating the endothelin B receptors by intravenous injection of IRL-1620 to prevent and repair the damage to the brain caused by Alzheimer’s disease,” said study co-author Seema Briyal, PhD.

Rats with AD showed impaired learning and memory and increased oxidative stress. “We found that treatment with IRL-1620 reversed these effects. Intravenous injection with the drug improved memory deficit by 50 to 60 percent and reduced oxidative stress by 45 to 50 percent,” Briyal explained. “We also found that treatment with IRL-1620 enhanced certain recovery processes within the AD-damaged brain, resulting in more new blood vessels and neuronal cells. This indicates reparative processes occurring in the damaged brain.”

According to Briyal and her mentor Anil Gulati, PhD, this is the first report to indicate that selective stimulation of the endothelin B receptors by IV injection of IRL-1620 improves memory, reduces oxidative stress and enhances neurovascular remodeling in animal model of Alzheimer’s disease. The study was supported by the Alzheimer’s Drug Discovery Foundation.

Gulati and Briyal will present “Stimulation of ETB Receptors by IRL-1620 Modulates the Progression of Alzheimer’s Disease” at a poster session on Friday, September 4, from 1 to 2:30 PM in Ballroom BCDEF of the Hyatt Regency Savannah.

NOTE TO JOURNALISTS: To read the full abstract or schedule an interview with a member of the research team, please contact the APS Communications Office or 301-634-7209. Find more research highlights in the APS Press Room.

Physiology is the study of how molecules, cells, tissues and organs function in health and disease. Established in 1887, the American Physiological Society (APS) was the first U.S. society in the biomedical sciences field. The Society represents more than 11,000 members and publishes 14 peer-reviewed journals with a worldwide readership.

 


RelatedItems

International Experts Talk Cancer, Sickle Cell, Diabetic Nephropathy Therapies at Endothelin Meeting in Savannah

Released September 2, 2015 - Endothelin (ET) plays a role in many functions throughout the body, including blood vessel constriction and blood pressure regulation and in a number of disease pathologies. Insights gained through the study of ET have great therapeutic potential for health and disease. As ET experts convene for the 14th International Conference on Endothelin: Physiology, Pathophysiology and Therapeutics, the translational aspect of ET research will take center stage during the “Endothelin Therapeutics—Where Are We?” symposium.

One Protein, Many Fascinating Roles

Released September 2, 2015 - Endothelin is a peptide produced by cells in the blood vessels and has powerful vessel-constricting effects. Although mainly associated with its role in blood pressure control and cardiovascular diseases, it continues to appear in other physiological functions and diseases. This symposium, taking place at 14th International Conference on Endothelin: Physiology, Pathophysiology and Therapeutics in Savannah, Ga., will discuss its roles in diabetes, cognitive decline, sickle cell disease and skin pigmentation.

New Hope for Lou: Unexplored Therapeutic Targets for ALS

Released September 3, 2015 - No cures exist for amyotrophic lateral sclerosis (ALS), and the only approved therapy slows the progression by only a few months. A new study identifies a promising unexplored avenue of treatment for ALS, the endothelin system. This study will be presented at 14th International Conference on Endothelin: Physiology, Pathophysiology and Therapeutics in Savannah, Ga.

Vitamin C: The Exercise Replacement?

Released September 4, 2015 - Exercise improves health in overweight and obese adults but can be hard to incorporate into a daily routine. New findings show that taking vitamin C supplements daily instead can have similar cardiovascular benefits as regular exercise in these adults. This study will be presented at 14th International Conference on Endothelin: Physiology, Pathophysiology and Therapeutics in Savannah, Ga.

The Brain May Show Signs of Aging Earlier than Old Age

Released March 17, 2016 - A new study published in Physiological Genomics suggests that the brain shows signs of aging earlier than old age. The study found that the microglia cells—the immune cells of the brain—in middle-aged mice already showed altered activity seen in microglia from older mice.

From: 
Email:  
To: 
Email:  
Subject: 
Message:

~/Custom.Templates/PressRelease.aspx